PharmacoEconomics & Outcomes News 680 - 15 Jun 2013

Velaglucerase-α in type 1 Gauchercost saving in Spain

Velaglucerase-α is a cost-saving option for thetreatment of type 1 Gaucher disease in Spain, accordingto the results of a study presented at the ISPOR meeting.

The study used a semi-Markov model with a decisiontree for the initial 2-year treatment period and a Markovhealth-state structure with a 39-year time horizon toassess the cost effectiveness of velaglucerase-α,compared with imiglucerase, from the perspective of theSpanish National Healthcare System.* Efficacy data werederived from the HGT-GCB-039 study, and resource usewas based on expert opinion.

The model predicted similar QALY gains in bothtreatment groups (25.55). The average cost per patientwas lower for velaglucerase-α, compared withimiglucerase (€7 265 332 vs €7 327 966; 2011 values).The cost difference was mainly due to the difference inadministration costs. Threshold sensitivity analysisshowed that velaglucerase-α would reach cost neutralityeven at a higher unit price.* The study was supported by Shire Pharmaceuticals Iberica.

Giraldo P, et al. Cost-Utility of Velaglucerase Alpha for the Treatment of Type IGaucher Disease in Spain. 18th Annual International Meeting of the InternationalSociety for Pharmacoeconomics and Outcomes Research : abstr. PSY48, 18 May2013. 803087554

1

PharmacoEconomics & Outcomes News 15 Jun 2013 No. 6801173-5503/10/0680-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved